Patents by Inventor Shaomeng Wang

Shaomeng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240166647
    Abstract: The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 23, 2024
    Inventors: Shaomeng Wang, Tianfeng Xu, Dimin Wu, Zhixiang Chen, Xin Han, Weiguo Xiang, Rohan Rej, Angelo Aguilar, Longchuan Bai
  • Publication number: 20240150360
    Abstract: The present disclosure relates to compounds of Formula (I), and the pharmaceutically A—(CH2)m—X—Y—Z—B1??I, acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer).
    Type: Application
    Filed: March 3, 2022
    Publication date: May 9, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Mi Wang
  • Patent number: 11944614
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 2, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Rohan Rej
  • Publication number: 20240059711
    Abstract: Described herein are compounds of Formula I and conjugates of Formula I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Yuk-Ming Siu, Rohan Rej, Ranjan Kumar Acharyya, Weiguo Xiang, Longchuan Bai
  • Publication number: 20240059704
    Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu
  • Publication number: 20230357249
    Abstract: The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 9, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao, Mingliang Wang, Rohan Rej
  • Publication number: 20230295200
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses as STAT5 and/or STAT6 inhibitors.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Shaomeng Wang, Atsunori Kaneshige, Longchuan Bai, Mi Wang, Jeanne Stuckey, Mingliang Wang, Renqi Xu
  • Publication number: 20230295197
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses as STAT5 and/or STAT6 degraders.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Shaomeng Wang, Atsunori Kaneshige, Longchuan Bai, Mi Wang, Jeanne Stuckey, Donna McEachern, Mingliang Wang, Renqi Xu
  • Publication number: 20230257365
    Abstract: The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 17, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao
  • Patent number: 11718613
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 8, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Publication number: 20230233690
    Abstract: The present disclosure provides compounds represented by Formula I: A-L-B1 and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: July 27, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Lijie Zhao
  • Publication number: 20230218765
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 19, 2021
    Publication date: July 13, 2023
    Inventors: Shaomeng Wang, Mingliang Wang, Jianfeng Lu, Mi Wang
  • Patent number: 11691989
    Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 4, 2023
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Hao Chen, Wenming Chen, Chao Li, Dongbo Li, Yu Jing, Guozhi Tang, Yunlong Zhou, Shaomeng Wang, Chao-Yie Yang
  • Publication number: 20230159573
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 25, 2023
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • Publication number: 20230133504
    Abstract: The present disclosure relates to methods of treating or preventing graft-versus-host disease (GVHD) comprising administering to the subject a pharmaceutically effective amount of a compound disclosed herein. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.
    Type: Application
    Filed: August 12, 2022
    Publication date: May 4, 2023
    Inventors: Pavan Reddy, Haibin Zhou, Dongchang Zhao, Shaomeng Wang, Longchuan Bai
  • Patent number: 11615346
    Abstract: Embodiments of the present disclosure provide a method and system for training a model by using training data. The training data includes a plurality of samples, each sample includes N features, and features in the plurality of samples form N feature columns, and the method includes: determining an importance value of each of the N feature columns; determining whether the importance value of each of the N feature columns satisfies a threshold condition; performing a dimension reduction on M feature columns to generate P feature columns in response to the determination that the importance values of the M feature columns do not satisfy the threshold condition, wherein M<N and P<M; merging (N?M) feature columns having importance values that satisfy the threshold condition and the generated P feature columns to obtain (N?M+P) feature columns; and training the model based on the training data including the (N?M+P) feature columns.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: March 28, 2023
    Assignee: Alibaba Group Holding Limited
    Inventors: Bin Dai, Shen Li, Xiaoyan Jiang, Xu Yang, Yuan Qi, Wei Chu, Shaomeng Wang, Zihao Fu
  • Publication number: 20230083015
    Abstract: The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or degraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 26, 2020
    Publication date: March 16, 2023
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • Patent number: 11548899
    Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 10, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Bing Zhou, Yang Hu, Chao-Yie Yang, Chong Qin
  • Publication number: 20220411432
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 29, 2022
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • Publication number: 20220396587
    Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 15, 2022
    Inventors: Guozhi Tang, Dongbo Li, Liugen Li, Xianchan Zha, Wenming Chen, Shaomeng Wang, Chao-Yie Yang